| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 274 | 2020 |
| Prognostic and predictive biomarker developments in multiple myeloma CT Wallington-Beddoe, RL Mynott Journal of hematology & oncology 14, 1-15, 2021 | 103 | 2021 |
| Resistance to proteasome inhibitors and other targeted therapies in myeloma CT Wallington‐Beddoe, M Sobieraj‐Teague, BJ Kuss, SM Pitson British Journal of Haematology 182 (1), 11-28, 2018 | 97 | 2018 |
| FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells CT Wallington-Beddoe, J Hewson, KF Bradstock, LJ Bendall Autophagy 7 (7), 707-715, 2011 | 90 | 2011 |
| Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing MYC Expression CT Wallington-Beddoe, JA Powell, D Tong, SM Pitson, KF Bradstock, ... Cancer research 74 (10), 2803-2815, 2014 | 88 | 2014 |
| Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia JA Powell, AC Lewis, W Zhu, J Toubia, MR Pitman, ... Blood, The Journal of the American Society of Hematology 129 (6), 771-782, 2017 | 85 | 2017 |
| Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies AC Lewis, CT Wallington-Beddoe, JA Powell, SM Pitson Cell Death Discovery 4 (1), 72, 2018 | 81 | 2018 |
| Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress CT Wallington-Beddoe, MK Bennett, K Vandyke, L Davies, JR Zebol, ... Oncotarget 8 (27), 43602, 2017 | 45 | 2017 |
| Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia AC Lewis, VS Pope, MN Tea, M Li, GO Nwosu, TM Nguyen, ... Blood, The Journal of the American Society of Hematology 139 (26), 3737-3751, 2022 | 29 | 2022 |
| Oncogenic properties of sphingosine kinases in haematological malignancies CT Wallington‐Beddoe, KF Bradstock, LJ Bendall British journal of haematology 161 (5), 623-638, 2013 | 28 | 2013 |
| Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia CT Wallington-Beddoe, AS Don, J Hewson, Q Qiao, RA Papa, RB Lock, ... PloS one 7 (5), e36429, 2012 | 27 | 2012 |
| Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple … CT Wallington-Beddoe, DJ Gottlieb, F Garvin, V Antonenas, MM Sartor Biology of blood and marrow transplantation 15 (11), 1386-1393, 2009 | 26 | 2009 |
| Sphingolipids and the unfolded protein response MK Bennett, CT Wallington-Beddoe, SM Pitson Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2019 | 25 | 2019 |
| Effectiveness of interferon alfa‐2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting D Kumar*, C Wallington‐Beddoe*, J George, R Lin, D Samarasinghe, ... Medical journal of Australia 178 (6), 267-271, 2003 | 20 | 2003 |
| Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition MK Bennett, M Li, MN Tea, MR Pitman, J Toubia, PPS Wang, D Anderson, ... Neoplasia 24 (1), 1-11, 2022 | 16 | 2022 |
| Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma RL Mynott, CT Wallington-Beddoe ACS Pharmacology & Translational Science 4 (3), 1050-1065, 2021 | 15 | 2021 |
| Identification of sphingosine kinase 1 as a therapeutic target in B‐lineage acute lymphoblastic leukaemia. CT Wallington‐Beddoe, V Xie, D Tong, JA Powell, AC Lewis, L Davies, ... British journal of haematology 184 (3), 2019 | 15 | 2019 |
| Novel therapies for multiple myeloma CT Wallington-Beddoe, SM Pitson Aging (Albany NY) 9 (8), 1857, 2017 | 12 | 2017 |
| Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma LM Ebert, K Vandyke, MZ Johan, M DeNichilo, LY Tan, KK Myo Min, ... Molecular oncology 16 (6), 1221-1240, 2022 | 11 | 2022 |
| Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the … S Jagannath, T Facon, AZ Badros, M Levy, P Moreau, S Delimpasi, ... Blood 138, 3793, 2021 | 11 | 2021 |
